ibrutinib,zilovertamab
oncternal therapeutics,abbvie,janssen
['zilovertamab', ' ibru', 'lymsm']
interesting to me that the phase 3 trial is of zilovertamab + ibrutinib rather than a less-toxic btki - we need a more nimble drug development process to allow this sort of iteration / improvement along the trial design process. #ash22 #lymsm
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer